<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sarah Feldman, MD, MPH
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christopher P Crum, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark H Einstein, MD, MS, FACS, FACOG
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alana Chakrabarti, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 04, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2179528551">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cervical cancer screening detects precancerous changes of the cervix (eg, cervical dysplasia), often making treatment possible before cervical cancer develops. Screening uses human papillomavirus (HPV) testing, cervical cytology (Pap test), or a combination of the two tests (eg, "co-testing").
        </p>
        <p>
         Techniques for obtaining specimens for cervical cytology and HPV testing are reviewed here. Screening strategies and interpretation of the cervical cytology report are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">
          "Screening for cervical cancer in resource-rich settings"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3205.html" rel="external">
          "Cervical cancer screening: The cytology and human papillomavirus report"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          HOW TO OBTAIN A SAMPLE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cell samples for cervical cytology and HPV testing are obtained during the speculum examination. Most often, the same specimen can be used for analysis of both cytology and HPV.
        </p>
        <p class="headingAnchor" id="H951763">
         <span class="h2">
          Specimens for cytology
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are two methods for preparing a specimen for cervical cytology (see
         <a class="local">
          'Sample collection'
         </a>
         below). For both methods, cells are obtained from the external surface of the cervix (ectocervix) and the cervical canal (endocervix) to evaluate the transformation zone (squamocolumnar junction), the area at greatest risk for neoplasia.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Collection device
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several collection devices are available for cervical cytology sampling. A spatula and a separate endocervical brush provide a specimen with more endocervical cells than when only a spatula is used [
         <a href="#rid1">
          1
         </a>
         ]. It is also slightly better for detecting any grade of cervical intraepithelial neoplasia (CIN) than the single broom device [
         <a href="#rid1">
          1
         </a>
         ]. Cotton tipped swabs should be avoided because they collect fewer endocervical cells and do not detect CIN as well as other devices [
         <a href="#rid2">
          2-4
         </a>
         ]. A meta-analysis of 36 randomized trials and six observational studies in patients undergoing conventional Pap smears found that the most commonly used spatula (Ayre spatula)  (
         <a class="graphic graphic_figure graphicRef72092" href="/z/d/graphic/72092.html" rel="external">
          figure 1
         </a>
         ) collected fewer endocervical cells than spatulas with extended tips (eg, Aylesbury), but both spatula types yielded similar diagnostic results [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Sample collection
         </span>
         <span class="headingEndMark">
          —
         </span>
         To obtain cells from the cervix:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use the spatula to circumferentially scrape the ectocervix (for liquid-based samples, use a plastic rather than a wooden spatula; wood or plastic is fine for conventional smears) [
         <a href="#rid5">
          5
         </a>
         ]. Sampling the ectocervix before the endocervix will minimize bleeding during sample collection. Obscuring blood in the sample interferes with interpretation of conventional Pap smears more than with liquid-based specimens.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Insert the endocervical brush into the endocervix so that the bristles nearest the examiner are inserted to the level of the external cervical os. Rotate the brush 180 degrees to obtain a sample.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alternatively, if a broom is used, insert the central bristles into the endocervix with the outer bristles in contact with the ectocervix. Rotate the broom in the same direction for five turns [
         <a href="#rid6">
          6
         </a>
         ]. Other devices on the market (eg, SpiraBrush, SoftBiopsy) have yet to be adequately studied with respect to safety and efficacy.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4908186">
         <span class="h3">
          Preparation methods
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are two methods for preparing a specimen for cervical cytology: liquid-based thin layer preparation and conventional Pap smear .
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For
         <strong>
          liquid-based thin layer cytology
         </strong>
         , the collecting device is placed into a liquid fixative solution and vigorously swirled or rotated ten times in the solution [
         <a href="#rid7">
          7
         </a>
         ]  (
         <a class="graphic graphic_figure graphicRef58546" href="/z/d/graphic/58546.html" rel="external">
          figure 2
         </a>
         ). When the liquid is processed by the cytology laboratory, loose cells are trapped onto a filter and then plated in a monolayer onto a glass slide.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For
         <strong>
          conventional Pap smears
         </strong>
         , the ectocervical spatula is smeared and the endocervical brush is rolled uniformly onto a single slide promptly after obtaining the specimens  (
         <a class="graphic graphic_figure graphicRef72393" href="/z/d/graphic/72393.html" rel="external">
          figure 3
         </a>
         ). The slide is then rapidly fixed to avoid air-drying; the usual fixatives are either ethyl ether plus 95 percent ethyl alcohol or 95 percent ethyl alcohol alone. If spray fixatives are used, the spray should be held at least 10 inches away from the slide to prevent disruption of cells by the propellant. If co-testing is being performed, an HPV specimen is collected and sent separately.
        </p>
        <p>
        </p>
        <p>
         For both methods, cells are obtained from the external surface of the cervix (ectocervix) and the cervical canal (endocervix) to evaluate the transformation zone (squamocolumnar junction), the area at greatest risk for neoplasia.
        </p>
        <p>
         An advantage of some liquid-based systems is the ability to use a single specimen for cytology and testing for HPV. With conventional smears, a separate HPV test specimen has to be obtained if co-testing is performed. (See
         <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">
          "Screening for cervical cancer in resource-rich settings", section on 'Types of screening and frequency'
         </a>
         .)
        </p>
        <p>
         Evidence regarding the screening efficacy with conventional and liquid-based Pap tests is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">
          "Screening for cervical cancer in resource-rich settings", section on 'Relative risks and benefits of each method'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3324219698">
         <span class="h3">
          Sample processing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cytopathologists review cervical cytology slides. The interpretation of cytologic smears is subject to considerable interobserver variability, particularly in the case of nondiagnostic squamous and glandular atypias (atypical squamous cells of undetermined significance and atypical glandular cells of undetermined significance) [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         In some settings, cytotechnologists and/or automated slide interpretation systems that use proprietary algorithms to perform initial review of the cytology slides to identify a subgroup of slides for subsequent evaluation by a cytopathologist. This subgroup consists of slides with high-powered fields that have specific abnormal cellular characteristics.
        </p>
        <p>
         One example of an automated slide interpretation system is the ThinPrep Imaging System, which is approved by the US Food and Drug Administration (FDA) for primary screening of slides. This system uses programmed algorithms to review each slide for areas of most concern. If abnormalities are found, the whole slide is reviewed by a cytopathologist. In one study, use of this device increased detection of high-grade squamous intraepithelial lesions (HSIL) by 38 percent and low-grade squamous intraepithelial lesions by 46 percent compared with manual screening [
         <a href="#rid9">
          9
         </a>
         ]. In another study, use of the imager resulted in fewer unsatisfactory slides than with conventional cytology (1.8 versus 3.1 percent) and better detection of HSIL [
         <a href="#rid10">
          10
         </a>
         ]. The clinical effectiveness of automated systems and their role in cervical cancer screening have not been definitively established.
        </p>
        <p>
         In the United States, quality assurance regulations require that laboratories rescreen 10 percent of randomly selected cervical cytology smears that were originally interpreted as negative [
         <a href="#rid11">
          11
         </a>
         ]. Manual rescreening of all negative cytology smears is time consuming, although rapid manual rescreening (30 to 120 seconds per slide) is feasible and practiced in the United Kingdom and elsewhere.
        </p>
        <p>
         Standardized terminology for reporting cervical cytology results was introduced with the Bethesda System in 1988, which was last revised in 2014  (
         <a class="graphic graphic_table graphicRef102346" href="/z/d/graphic/102346.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid12">
          12-14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3205.html" rel="external">
          "Cervical cancer screening: The cytology and human papillomavirus report"
         </a>
         .)
        </p>
        <p>
         Most laboratories offer other tests to assist in reading abnormal cytology slides that have an increased detection of cervical abnormalities. These include commercial tests that detect molecular markers (eg, dual stain p16/Ki-67) that are highly associated with clinically relevant cervical neoplasia; testing negative for these markers is associated with almost no risk of disease [
         <a href="#rid15">
          15-18
         </a>
         ]. Such testing is quickly becoming routine for cytopathologists to order as it aids in their diagnosis of equivocal cervical cytology (eg, atypical squamous cells of undetermined significance [ASCUS], low-grade squamous intraepithelial lesion [LSIL]).
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          HPV testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         HPV testing identifies oncogenic (ie, high-risk) HPV subtypes that are associated with cervical cancer  (
         <a class="graphic graphic_table graphicRef76394" href="/z/d/graphic/76394.html" rel="external">
          table 2
         </a>
         ). The subtypes that are tested have slight variation across the various testing systems, but all test for at least the 13 most common types. HPV genotyping refers to testing for individual HPV types, usually HPV 16 or 18, but some tests may also include HPV 45. (See
         <a class="medical medical_review" href="/z/d/html/8031.html" rel="external">
          "Virology of human papillomavirus infections and the link to cancer", section on 'HPV Genotypes and risk of cancer'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8031.html" rel="external">
          "Virology of human papillomavirus infections and the link to cancer", section on 'Molecular pathogenesis'
         </a>
         .)
        </p>
        <p>
         HPV testing systems are approved for either primary HPV testing (without cervical cytology) or co-testing (with cervical cytology)  (
         <a class="graphic graphic_table graphicRef129179" href="/z/d/graphic/129179.html" rel="external">
          table 3
         </a>
         ). In the United States, there are only two FDA-approved tests for primary HPV screening and five that are approved for co-testing. Tests that are FDA approved for co-testing are also suitable for reflex testing in response to a cervical cytology result of atypical squamous cells of undetermined significance (ASC-US). This is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">
          "Screening for cervical cancer in resource-rich settings", section on 'Types of screening and frequency'
         </a>
         .)
        </p>
        <p>
         Clinical trial data vary for each HPV test. While there is also variability among laboratories regarding performance (ie, identifying cervical intraepithelial neoplasia [CIN] 2 or greater), all of the tests are highly sensitive in detecting HPV. As testing technology evolves, new tests are developed, or there are expanded approvals for previously approved tests, cervical screening testing management guidelines may take these subtle performance differences into account [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H853915922">
         <span class="h3">
          Cervical testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specimens for HPV testing can be collected from the endocervix using a cervical spatula or cervical brush, which is then placed in HPV test transport medium [
         <a href="#rid20">
          20
         </a>
         ]. With some liquid-based cytology sampling systems, the same specimen can be used for HPV testing and cytology.
        </p>
        <p>
         Self-collection of an HPV sample by the patient can also be performed; while this practice is well described in resource-limited settings, its use in resource-rich settings is more limited and self-sampling tests are not approved by the FDA. For self-collection, patients can collect samples from the vagina using a tampon, Dacron or cotton swab, cytobrush, or cervicovaginal lavage. Self-collection may increase screening uptake, especially for patients with barriers to health care. In randomized trials in the United States evaluating cervical cancer screening uptake, those with access to self-sampling HPV kits compared with usual care (ie, cervical cancer screening reminders) had higher rates of screening uptake [
         <a href="#rid21">
          21-23
         </a>
         ]. A large, national, multicentric screening trial is underway [
         <a href="#rid24">
          24
         </a>
         ]. Self-collection is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/7575.html" rel="external">
          "Screening for cervical cancer in resource-rich settings", section on 'Types of screening and frequency'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3202.html" rel="external">
          "Screening for cervical cancer in resource-limited settings", section on 'Self-collected samples'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H649248041">
         <span class="h3">
          Investigational strategies
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Urine testing
         </strong>
         – Urine testing for HPV has been proposed, but is not clinically available [
         <a href="#rid25">
          25,26
         </a>
         ]. While urine testing does not appear to be as sensitive as cervical testing, it may have potential in large research studies or as an alternative test in settings where routine cervicovaginal examinations are not economically feasible or less likely to be performed due to cultural barriers.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Menstrual blood sampling
         </strong>
         – Menstrual blood sampling for HPV testing has been described and may be a convenient approach for cervical cancer screening in premenopausal patients [
         <a href="#rid27">
          27,28
         </a>
         ], but further studies are needed.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Additional tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         Additional testing that may be performed during examination of the cervix includes:
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Gonorrhea, chlamydia, and trichomonas
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is common practice to collect the cytology sample before testing for cervical infection, if indicated. However, there is no evidence that the order in which the samples are obtained affects cytology results [
         <a href="#rid29">
          29
         </a>
         ]. Liquid-based cytology systems allow testing for cytology, HPV, gonorrhea, chlamydia, and trichomonas from a single specimen. (See
         <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">
          "Screening for sexually transmitted infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15893.html" rel="external">
          "Clinical manifestations and diagnosis of
          <i>
           Neisseria gonorrhoeae
          </i>
          infection in adults and adolescents", section on 'Performance on urogenital specimens'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/83019.html" rel="external">
          "Clinical manifestations and diagnosis of
          <i>
           Chlamydia trachomatis
          </i>
          infections", section on 'Diagnosis of chlamydial infections'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5453.html" rel="external">
          "Trichomoniasis: Clinical manifestations and diagnosis", section on 'Less accurate'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Biopsy of visible lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         During Pap testing, any lesion that is raised, friable, or has the appearance of condyloma should be biopsied, regardless of previous cytology results or other risk factors for cervical cancer [
         <a href="#rid30">
          30
         </a>
         ]. The only visible lesions that do not require biopsy are Nabothian cysts and only when this diagnosis is confirmed by an experienced examiner. (See
         <a class="medical medical_review" href="/z/d/html/5428.html" rel="external">
          "Benign cervical lesions and congenital anomalies of the cervix", section on 'Nabothian cysts'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H853915965">
         <span class="h2">
          Anatomic barriers
         </span>
         <span class="headingEndMark">
          —
         </span>
         In some patients, the cervix is difficult to visualize on pelvic examination. Factors that may make visualization difficult include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High body mass index [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior cesarean section.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A uterus that is sharply anteverted or retroverted.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Obliteration of the vaginal fornices (from menopause-induced vaginal atrophy, prior pelvic radiation, or vaginal graft-versus-host disease).
        </p>
        <p>
        </p>
        <p>
         If the clinician cannot see the cervix, options include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use a longer Graves or Pederson speculum to reach the vaginal apex; press the speculum along the posterior vaginal wall until the apex is reached and then open the speculum slowly.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform a bimanual examination to palpate the cervix and identify its location. In patients with obliteration of the vaginal fornices, palpation often allows the examiner to differentiate the firm cervical tissue from the surrounding vaginal walls. Lubricant is sometimes avoided as it can interfere with the ability to analyze the Pap specimen. (See
         <a class="local">
          'Gel lubricants and other contaminants'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Improve visualization by optimizing the patient's position. In dorsal lithotomy, the following modifications can be used:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Ensure that the patient's legs are sufficiently abducted. The patient may need to move toward the examiner. Care should be taken if the patient has knee or hip mobility issues.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Elevate the sacrum by placing an object (bedpan, folded up sheet or towel) under the patient's hips.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Confirm that the patient has a cervix (some patients who have undergone a total hysterectomy do not give an accurate surgical history).
        </p>
        <p>
        </p>
        <p>
         In patients with cervical stenosis, it may be difficult to obtain an endocervical sample, thus resulting in an insufficient result. When it is difficult to insert the sampling device into the endocervix, one of the following techniques may facilitate collection of an endocervical sample:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Perform Pap testing during menses. Menstrual blood often slightly dilates the cervix.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grasp the anterior or posterior lip of the cervix with a single-tooth tenaculum. Applying gentle traction will stabilize the cervix and may provide enough counter-tension to insert a sampling device into the external cervical os.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use a small mechanical dilator to dilate the cervix.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administer a para- or intracervical block to help with patient discomfort.
        </p>
        <p>
        </p>
        <p>
         Follow-up in patients with a Pap test with absence of endocervical cells/transformation zone component is discussed separately [
         <a href="#rid32">
          32-35
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3205.html" rel="external">
          "Cervical cancer screening: The cytology and human papillomavirus report", section on 'Absent EC/TZ'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H22">
         <span class="h1">
          FACTORS WITH LIMITED OR NO EFFECTS ON SAMPLING
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is perception that any action that may remove cells from the cervix (eg, prior Pap sampling, cervical cultures, swabbing) will impair Pap test cellularity, and thus compromise efficacy for cervical cancer screening. However, data do not support these concerns.
        </p>
        <p>
         The factors discussed in this section relate to the effects on cytology or HPV testing or both.
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Menses or other genital tract bleeding
         </span>
         <span class="headingEndMark">
          —
         </span>
         Historically, patients planning to have screening cytology for cervical cancer have been advised to avoid testing during menses or other genital tract bleeding. We suggest performing rather than deferring the test, unless the blood cannot be cleaned from the cervix. Cleaning the cervix with a large cotton swab will remove obscuring blood and appears to have a minimal or no effect on sample cellularity and has no effect on detection of HPV [
         <a href="#rid36">
          36,37
         </a>
         ].
        </p>
        <p>
         If there is obscuring blood, conventional Pap smears are more likely to be unsatisfactory for interpretation than liquid-based methods because liquid-based techniques filter out red blood cells. This was demonstrated in a population-based retrospective study in the Netherlands in which over 100,000 patients who reported having regular menstrual cycles were screened for cervical cancer using the conventional Pap smear [
         <a href="#rid5">
          5
         </a>
         ]. The rate of unsatisfactory smears was 23 percent during cycle days 0 to 3 versus 2 percent for the remainder of the cycle.
        </p>
        <p>
         For liquid-based Pap tests, timing during the menstrual cycle does not appear to have a clinically significant effect on cytologic results [
         <a href="#rid38">
          38,39
         </a>
         ]. This was illustrated by a large study in which 5060 patients with initial cytology showing atypical squamous cells of undetermined significance (ASC-US) or low-grade squamous intraepithelial lesions (LSIL) had over 20,000 liquid-based Pap tests [
         <a href="#rid39">
          39
         </a>
         ]. The phase of the menstrual cycle did not have a significant effect on the rate of unsatisfactory specimens. Although the detection of LSIL or more severe abnormalities was slightly higher in the mid- versus early or late cycle (mid-cycle: 20 percent, early and late cycle: 18 percent), this difference is unlikely to be clinically significant.
        </p>
        <p class="headingAnchor" id="H24">
         <span class="h2">
          Interval between Pap tests
         </span>
         <span class="headingEndMark">
          —
         </span>
         A Pap test may need to be repeated after a brief interval if the sample is unsatisfactory or at the time of colposcopy. A short interval between Pap tests (15 to 30 days) does not appear to affect sensitivity for detection of cervical neoplasia [
         <a href="#rid40">
          40,41
         </a>
         ].
        </p>
        <p>
         The concern about a short interval between Pap tests is based on the hypothesis that previous scraping for cytology will remove the most superficial layer of cervical cells, where a potential abnormality is most likely to occur. It will then take a period of time (generally estimated as up to two months) for the superficial cells to regenerate [
         <a href="#rid42">
          42
         </a>
         ]. Thus, if sampling is performed too soon, the underlying cells may be sampled and appear normal, yielding a false negative test.
        </p>
        <p>
         The most informative study of the optimum interval between Pap smears evaluated liquid-based Pap tests and HPV testing results in 5055 patients with initial Pap tests that showed either ASC-US or LSIL [
         <a href="#rid41">
          41
         </a>
         ]. Sensitivity of repeat specimens was assessed by comparing cytology with histology in patients with cervical intraepithelial neoplasia 3 or carcinoma. The interval from initial to repeat Pap test in these patients was 8 to 184 days. Adequacy of the sample did not appear to be affected, since cellularity of the sample and HPV viral load did not vary with Pap intervals. In addition, Pap test interval (15 to 120 days) did not significantly affect the finding of abnormal cytology. In fact, the likelihood of a Pap result of LSIL was higher after a shorter versus a longer interval (≤30 days [30 percent] versus &gt;120 days [20 percent]); this likely represents regression of LSIL with time.
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h2">
          Gel lubricants and other contaminants
         </span>
         <span class="headingEndMark">
          —
         </span>
         Contaminants, such as gel lubricant (eg, from an examiner's hand before a Pap test is performed), vaginal discharge, semen, spermicide, or intravaginal medications, have been thought to affect cervical sampling. On a conventional smear, the concern is that these may make the smear thick and difficult to read or, in the case of lubricants that include carbomers or carbopol polymers, may interfere with sample interpretation. In addition, in our experience, a sample is often returned by the laboratory with a note regarding difficulty in interpretation because of lubricant. Thus, if large amounts of vaginal contaminants are present, the discharge should be removed gently with a large cotton swab. Routine removal of a small amount of discharge or other contaminants is unnecessary. Clinicians should also check with their cytology laboratory to determine approved lubricants.
        </p>
        <p>
         In general, studies have not shown an adverse impact of lubricants on cervical cytology interpretation [
         <a href="#rid43">
          43-47
         </a>
         ]. Studies of use of
         <a class="drug drug_general" data-topicid="10170" href="/z/d/drug information/10170.html" rel="external">
          nonoxynol-9
         </a>
         spermicide have had conflicting results regarding cervical cytology changes [
         <a href="#rid48">
          48,49
         </a>
         ]. The spermicide nonoxynol-9 is not active against HPV, but detergents, such as sodium dodecyl sulfate (SDS), do inactivate HPV, and a spermicide/SDS combination could be useful in preventing HPV transmission [
         <a href="#rid50">
          50,51
         </a>
         ]. Nonoxynol-9 spermicide is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/3265.html" rel="external">
          "Pericoital (on demand) contraception: Diaphragm, cervical cap, spermicides, and sponge", section on 'Vaginal spermicide and pH regulator gel'
         </a>
         .)
        </p>
        <p>
         As discussed above, testing for Neisseria gonorrhea and Chlamydia trachomatis cervical infection is often performed concurrently with cervical cytology. Many clinicians avoid use of gel lubricants prior to testing for these bacteria, since some lubricants are bacteriostatic (eg, those containing
         <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">
          chlorhexidine
         </a>
         gluconate). However, one of the studies described above also evaluated DNA probe testing in 5535 patients in whom gel or water was used to lubricate the speculum prior to testing [
         <a href="#rid43">
          43
         </a>
         ]. No significant differences were found between groups in the detection rate of chlamydia (1.5 percent in both groups); the gonorrhea infection rate was too low to analyze. (See
         <a class="medical medical_review" href="/z/d/html/7596.html" rel="external">
          "Screening for sexually transmitted infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h2">
          Vaginal intercourse, douching, and tampon use
         </span>
         <span class="headingEndMark">
          —
         </span>
         While historically patients were advised to refrain from vaginal activities (eg, douching, tampon use, sexual intercourse) during the 48 hours prior to a Pap test, advising patients to avoid vaginal activities may be cumbersome to clinicians and make timely scheduling of Pap tests difficult for patients. There are few data that directly assess the effect of vaginal activities on cervical cytology or HPV testing, and we do not inquire about these activities prior to performing these tests.
        </p>
        <p>
         In a study of HPV testing in which patients performed self-sampling with synthetic polyester swabs or a tampon, there was no significant effect on HPV detection when vaginal intercourse occurred within 48 hours of sampling [
         <a href="#rid52">
          52
         </a>
         ]. Although it is possible that HPV detected in cytology samples following recent sexual activity could be derived from the male partner, this should not alter the standard management algorithm. In a subsequent study evaluating 132 patients with abnormal cervical cytology, HPV detection was similar before and after douching (sensitivity was 98 percent before douching; 96 percent after douching); results of the effect of douching on cytology results were not reported [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1758946248">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117738.html" rel="external">
          "Society guideline links: Cervical cancer screening, prevention, and management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/16110.html" rel="external">
          "Patient education: Cervical cancer screening tests (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Beyond the Basics topics (see
         <a class="medical medical_patient" href="/z/d/html/8412.html" rel="external">
          "Patient education: Cervical cancer screening (Beyond the Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H28">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical significance
         </strong>
         – Cervical cancer screening tests use human papillomavirus (HPV) testing, cervical cytology (Pap test), or a combination of the two tests (eg, "co-testing") to detect cellular changes of the cervix (eg, cervical dysplasia) or infection with types of HPV that may predispose patients to invasive cervical cancer. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Specimens for cytology
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         With liquid-based methods, the specimen is placed into a liquid fixative solution  (
         <a class="graphic graphic_figure graphicRef58546" href="/z/d/graphic/58546.html" rel="external">
          figure 2
         </a>
         ). Conventional cervical smears are performed by smearing the specimen on a slide. Both methods are referred to as cervical cytology or a Pap test. (See
         <a class="local">
          'Preparation methods'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Several types of collection devices can be used for cervical cytology sampling. (See
         <a class="local">
          'Collection device'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          HPV testing
         </strong>
         – HPV testing detects types of the virus that are associated with a high risk of cervical neoplasia. HPV testing systems approved for either primary HPV testing (without cervical cytology) or co-testing (with cervical cytology) are shown in the table  (
         <a class="graphic graphic_table graphicRef129179" href="/z/d/graphic/129179.html" rel="external">
          table 3
         </a>
         ). (See
         <a class="local">
          'HPV testing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Factors with limited or no effects on sampling
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Menses (or other vaginal bleeding), sexual intercourse, douching, tampon use, and a short interval between Pap testing do not appear to diminish the ability to diagnose cervical abnormalities or HPV infection. (See
         <a class="local">
          'Factors with limited or no effects on sampling'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of some lubricants before performing a Pap test may interfere with results of cytology. Clinicians should check with their cytology laboratory for approved lubricants. (See
         <a class="local">
          'Gel lubricants and other contaminants'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Marchand L, Mundt M, Klein G, Agarwal SC. Optimal collection technique and devices for a quality pap smear. WMJ 2005; 104:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martin-Hirsch P, Jarvis G, Kitchener H, Lilford R. Collection devices for obtaining cervical cytology samples. Cochrane Database Syst Rev 2000; :CD001036.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arbyn M, Herbert A, Schenck U, et al. European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology. Cytopathology 2007; 18:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrison DD, Hernandez E, Dunton CJ. Endocervical brush versus cotton swab for obtaining cervical smears at a clinic. A cost comparison. J Reprod Med 1993; 38:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vooijs GP, van der Graaf Y, Elias AG. Cellular composition of cervical smears in relation to the day of the menstrual cycle and the method of contraception. Acta Cytol 1987; 31:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin 2002; 52:342.
          </a>
         </li>
         <li class="breakAll">
          http://www.thinprep.com/hcp/specimen_collection/brush_spatula.html (Accessed on April 25, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stoler MH, Schiffman M, Atypical Squamous Cells of Undetermined Significance-Low-grade Squamous Intraepithelial Lesion Triage Study (ALTS) Group. Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study. JAMA 2001; 285:1500.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lozano R. Comparison of computer-assisted and manual screening of cervical cytology. Gynecol Oncol 2007; 104:134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davey E, d'Assuncao J, Irwig L, et al. Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study. BMJ 2007; 335:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tabbara SO, Sidawy MK. Evaluation of the 10% rescreen of negative gynecologic smears as a quality assurance measure. Diagn Cytopathol 1996; 14:84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop. JAMA 1989; 262:931.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002; 287:2114.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nayar R, Wilbur DC. The Pap Test and Bethesda 2014: "The reports of my demise have been greatly exaggerated. (after a quotation from Mark Twain)". J Low Genit Tract Dis 2015; 19:175.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wentzensen N, Fetterman B, Castle PE, et al. p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women. J Natl Cancer Inst 2015; 107:djv257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wentzensen N, Schwartz L, Zuna RE, et al. Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population. Clin Cancer Res 2012; 18:4154.
          </a>
         </li>
         <li class="breakAll">
          ASCCP Risk-Based Management Consensus Guidelines http://www.asccp.org/consensus-guidelines (Accessed on May 22, 2019).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Darragh TM, Colgan TJ, Thomas Cox J, et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013; 32:76.
          </a>
         </li>
         <li class="breakAll">
          American Society for Colposcopy and Cervical Pathology Executive Board, 2017, personal communication.
         </li>
         <li class="breakAll">
          http://www.thehpvtest.com/~/media/5C4BD0982BED4E3788F65B36AF829AAD.ashx (Accessed on April 30, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winer RL, Tiro JA, Miglioretti DL, et al. Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 2018; 64:77.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winer RL, Lin J, Tiro JA, et al. Effect of Patient Characteristics on Uptake of Screening Using a Mailed Human Papillomavirus Self-sampling Kit: A Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open 2022; 5:e2244343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Winer RL, Lin J, Anderson ML, et al. Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial. JAMA 2023; 330:1971.
          </a>
         </li>
         <li class="breakAll">
          NCI Cervical Cancer ‘Last Mile’ Initiative. National Cancer Institute. Available at: https://prevention.cancer.gov/major-programs/nci-cervical-cancer-last-mile-initiative (Accessed on July 05, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pathak N, Dodds J, Zamora J, Khan K. Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis. BMJ 2014; 349:g5264.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitchener HC, Owens GL. Urine testing for HPV. BMJ 2014; 349:g5542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhang J, Tian X, Chen Y, et al. Feasibility and Accuracy of Menstrual Blood Testing for High-risk Human Papillomavirus Detection With Capture Sequencing. JAMA Netw Open 2021; 4:e2140644.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naseri S, Young S, Cruz G, Blumenthal PD. Screening for High-Risk Human Papillomavirus Using Passive, Self-Collected Menstrual Blood. Obstet Gynecol 2022; 140:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hildesheim A, Bratti MC, Edwards RP, et al. Collection of cervical secretions does not adversely affect Pap smears taken immediately afterward. Clin Diagn Lab Immunol 1998; 5:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Partridge EE, Abu-Rustum NR, Campos SM, et al. Cervical cancer screening. J Natl Compr Canc Netw 2010; 8:1358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clarke MA, Fetterman B, Cheung LC, et al. Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer. J Clin Oncol 2018; 36:1184.
          </a>
         </li>
         <li class="breakAll">
          HC2 High-Risk HPV DNA Test. US Food and Drug Administration (FDA) approved product information. (Available online at https://www.accessdata.fda.gov/cdrh_docs/pdf/P890064S009c.pdf).
         </li>
         <li class="breakAll">
          Aptima HPV Assay. Hologic. (Available at https://www.hologic.com/sites/default/files/2018-08/AW-12820_002_01.pdf).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cui M, Chan N, Liu M, et al. Clinical performance of Roche Cobas 4800 HPV Test. J Clin Microbiol 2014; 52:2210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook DA, Mei W, Smith LW, et al. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer 2015; 15:968.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotaska AJ, Matisic JP. Cervical cleaning improves Pap smear quality. CMAJ 2003; 169:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hans N, Cave AJ, Szafran O, et al. Papanicolaou smears: to swab or not to swab. Can Fam Physician 2007; 53:1328.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernstein SJ, Sanchez-Ramos L, Ndubisi B. Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy. Am J Obstet Gynecol 2001; 185:308.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sherman ME, Carreon JD, Schiffman M. Performance of cytology and human papillomavirus testing in relation to the menstrual cycle. Br J Cancer 2006; 94:1690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishop JW, Hartinger JS, Pawlick GF. Time interval effect on repeat cervical smear results. Acta Cytol 1997; 41:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeronimo J, Khan MJ, Schiffman M, et al. Does the interval between papanicolaou tests influence the quality of cytology? Cancer 2005; 105:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           KOSS LG, STEWART F, FOOTE FW, et al. SOME HISTOLOGICAL ASPECTS OF BEHAVIOR OF EPIDERMOID CARCINOMA IN SITU AND RELATED LESIONS OF THE UTERINE CERVIX. A LONG-TERM PROSPECTIVE STUDY. Cancer 1963; 16:1160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffith WF, Stuart GS, Gluck KL, Heartwell SF. Vaginal speculum lubrication and its effects on cervical cytology and microbiology. Contraception 2005; 72:60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amies AM, Miller L, Lee SK, Koutsky L. The effect of vaginal speculum lubrication on the rate of unsatisfactory cervical cytology diagnosis. Obstet Gynecol 2002; 100:889.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hathaway JK, Pathak PK, Maney R. Is liquid-based pap testing affected by water-based lubricant? Obstet Gynecol 2006; 107:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harer WB, Valenzuela G Jr, Lebo D. Lubrication of the vaginal introitus and speculum does not affect Papanicolaou smears. Obstet Gynecol 2002; 100:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tavernier LA, Connor PD, Gates D. Water vs gel lubricant for cervical cytology specimens. J Fam Pract 2003; 52:701.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Poindexter AN 3rd, Levine H, Sangi-Haghpeykar H, et al. Comparison of spermicides on vulvar, vaginal, and cervical mucosa. Contraception 1996; 53:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halpern V, Rountree W, Raymond EG, Law M. The effects of spermicides containing nonoxynol-9 on cervical cytology. Contraception 2008; 77:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Auborn KJ, Carter TH. Treatment of human papillomavirus gynecologic infections. Clin Lab Med 2000; 20:407.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marais D, Carrara H, Kay P, et al. The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers. Virus Res 2006; 121:220.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harper DM, Longacre MR, Noll WW, et al. Factors affecting the detection rate of human papillomavirus. Ann Fam Med 2003; 1:221.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chen FC, Shaw SW, Cheng PJ, et al. Diagnosis of human papillomavirus infection by abnormal cervical cytology is highly reproducible after vaginal douching. Taiwan J Obstet Gynecol 2008; 47:412.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 3219 Version 45.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16218317" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Optimal collection technique and devices for a quality pap smear.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10908482" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Collection devices for obtaining cervical cytology samples.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17573762" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : European guidelines for quality assurance in cervical cancer screening: recommendations for collecting samples for conventional and liquid-based cytology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8501736" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Endocervical brush versus cotton swab for obtaining cervical smears at a clinic. A cost comparison.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3604536" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Cellular composition of cervical smears in relation to the day of the menstrual cycle and the method of contraception.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12469763" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : American Cancer Society guideline for the early detection of cervical neoplasia and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12469763" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : American Cancer Society guideline for the early detection of cervical neoplasia and cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11255427" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Interobserver reproducibility of cervical cytologic and histologic interpretations: realistic estimates from the ASCUS-LSIL Triage Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16959306" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Comparison of computer-assisted and manual screening of cervical cytology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17604301" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Accuracy of reading liquid based cytology slides using the ThinPrep Imager compared with conventional cytology: prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8834084" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Evaluation of the 10% rescreen of negative gynecologic smears as a quality assurance measure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2754794" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : The 1988 Bethesda System for reporting cervical/vaginal cytological diagnoses. National Cancer Institute Workshop.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11966386" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The 2001 Bethesda System: terminology for reporting results of cervical cytology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25943863" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The Pap Test and Bethesda 2014: "The reports of my demise have been greatly exaggerated. (after a quotation from Mark Twain)".
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26376685" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : p16/Ki-67 Dual Stain Cytology for Detection of Cervical Precancer in HPV-Positive Women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22675168" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22675168" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Performance of p16/Ki-67 immunostaining to detect cervical cancer precursors in a colposcopy referral population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23202792" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23202792" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23202792" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29113956" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36449291" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Effect of Patient Characteristics on Uptake of Screening Using a Mailed Human Papillomavirus Self-sampling Kit: A Secondary Analysis of a Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38015219" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/38015219" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Strategies to Increase Cervical Cancer Screening With Mailed Human Papillomavirus Self-Sampling Kits: A Randomized Clinical Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25232064" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Accuracy of urinary human papillomavirus testing for presence of cervical HPV: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25230583" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Urine testing for HPV.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34940863" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Feasibility and Accuracy of Menstrual Blood Testing for High-risk Human Papillomavirus Detection With Capture Sequencing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35926207" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Screening for High-Risk Human Papillomavirus Using Passive, Self-Collected Menstrual Blood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9665954" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Collection of cervical secretions does not adversely affect Pap smears taken immediately afterward.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21147902" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Cervical cancer screening.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29356609" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29356609" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29356609" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24719443" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Clinical performance of Roche Cobas 4800 HPV Test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26674353" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Comparison of the Roche cobas®4800 and Digene Hybrid Capture®2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14517124" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Cervical cleaning improves Pap smear quality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17872849" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Papanicolaou smears: to swab or not to swab.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11518884" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16670716" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Performance of cytology and human papillomavirus testing in relation to the menstrual cycle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9100753" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Time interval effect on repeat cervical smear results.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15822121" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Does the interval between papanicolaou tests influence the quality of cytology?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14065082" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : SOME HISTOLOGICAL ASPECTS OF BEHAVIOR OF EPIDERMOID CARCINOMA IN SITU AND RELATED LESIONS OF THE UTERINE CERVIX. A LONG-TERM PROSPECTIVE STUDY.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15964294" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Vaginal speculum lubrication and its effects on cervical cytology and microbiology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12423848" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : The effect of vaginal speculum lubrication on the rate of unsatisfactory cervical cytology diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16394041" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Is liquid-based pap testing affected by water-based lubricant?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12423847" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Lubrication of the vaginal introitus and speculum does not affect Papanicolaou smears.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12967542" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Water vs gel lubricant for cervical cytology specimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8689878" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Comparison of spermicides on vulvar, vaginal, and cervical mucosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18279690" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The effects of spermicides containing nonoxynol-9 on cervical cytology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10863647" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Treatment of human papillomavirus gynecologic infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16860426" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The impact of the use of COL-1492, a nonoxynol-9 vaginal gel, on the presence of cervical human papillomavirus in female sex workers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15055412" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Factors affecting the detection rate of human papillomavirus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19126507" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Diagnosis of human papillomavirus infection by abnormal cervical cytology is highly reproducible after vaginal douching.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
